MarketWatchCenter·
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Read at MarketWatch →
Markets · 1 sources covering this
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/fb3523536cb1d7d755a1b4a5139ffb58d2797345" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Major drugmaker loses $27 billion in market value after failed trial"></iframe>
